Oct2018
Gastric Cancer: Artificial Intelligence helps identify novel single biomarkers to guide targeted precision medicine
Gastric Cancer: Ariana and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer. Gastric cancer is the second most common cause of cancer-related deaths in the world. Adapting the therapeutic choice to the molecular diversity of the disease is a […]
Sep2018
Artificial Intelligence enables first biomarker driven precision medicine therapy against Alzheimer
Ariana Pharma helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase 2a clinical trial. Ariana’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73. Professor Harald Hampel, M.D., Ph.D., presenting results at the AAIC […]
Sep2018
Recombio and Ariana Pharma Identify Lung Cancer Patients Most Benefiting from Racotumomab Vaccine Therapy
Ariana has applied its advanced Artificial Intelligence platform KEM® and identified best responders to Racotumomab based on patients’ immune profile. Racotumab is a therapeutic vaccine developed by Recombio against non-small cell lung cancer (NSCLC), the most frequent type of lung cancers. Paris, Cambridge (MA) and Madrid– September 6, 2018 – Ariana Pharma (Paris, France and […]
Aug2018
Applying the cancer playbook to find treatment for Alzheimer’s disease
Applying the cancer playbook to find treatment for Alzheimer’s disease: see how Ariana’s KEM Artificial Intelligence platform is helping Anavex Life Sciences develop the first targeted therapy against Alzheimer’s disease. “NEW YORK – July 25, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics […]
Jan2018
Autism and automatic analysis of hand movements
Kinematics could provide earlier and more specific information than clinicians on developmental problems in general, and those specific to Autism Spectrum Disorder in particular, a published study by Ariana and Necker Children Hospital finds. Developmental Trajectories of Hand Movements in Typical Infants and those at Risk of Developmental Disorders: An Observational Study of Kinematics during […]
Jan2018
Ariana’s KEM® analysis shows positive impact on patient Quality of Life for ValiSeek VAL401 in Phase II trial for NSCLC patients
Further positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. VAL401 treatment has a measureable improvement on patient Quality of Life, in addition to a significant impact on survival. London, Paris and Boston, 16 January 2018: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, […]
Dec2017
Ariana®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients
London, Paris and Boston, 12 December 2017: Ariana Pharma and ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today provided a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek. Using Ariana’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, the data analysis demonstrates that the VAL401 […]
Nov2017
CTAD 2017 (Boston, USA | 1-4 Nov)
Dr Mohammad Afshar (Ariana CEO) is presenting on the analysis of Phase 2a trial results using Ariana’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease […]
Oct2017
Anavex incorporating Ariana’s KEM® AI platform in Alzheimer’s precision medicine approach
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease PatientsANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed.Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success […]
Jun2017
WIN 2017 (Paris | Jun 26-27)
Meet the Ariana team of Dr Mohammad Afshar (CEO) and Dr Mariana Kuras (CTO) at the WIN 2017 Symposium this week. The conference program will elaborate the theme ‘Expediting Global Innovation in Precision Cancer Medicine’ and is the place to be to learn about the latest in cancer research from leading practioners.